Showing results (1-10 of 296) with videos related to
Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2017
Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer OutcomesXavier Paoletti, Damien Drubay, Laurence ColletteContemporary Clinical Trials Communications|February 15, 2020
Proportional odds assumption for modeling longitudinal ordinal multiple toxicity outcomes in dose finding studies of targeted agents: A pooled analysis of 54 studiesDamien Drubay, Laurence Collette, Xavier PaolettiJournal of the National Cancer Institute|March 7, 2019
Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II DoseMaria-Athina Altzerinakou, Laurence Collette, Xavier PaolettiBioinformatics (Oxford, England)|January 18, 2018
A benchmark study of scoring methods for non-coding mutationsDamien Drubay, Daniel Gautheret, Stefan MichielsJournal of Bioinformatics and Computational Biology|October 26, 2022
A non-parametric Bayesian joint model for latent individual molecular profiles and survival in oncologySarah-Laure Rincourt, Stefan Michiels, Damien DrubayCancer Informatics|July 21, 2022
Complex Disease Individual Molecular Characterization Using Infinite Sparse Graphical Independent Component AnalysisSarah-Laure Rincourt, Stefan Michiels, Damien DrubayCancer Letters|October 4, 2015
Mining the coding and non-coding genome for cancer driversJia Li, Damien Drubay, Stefan Michiels, et al.Nature Reviews. Urology|June 6, 2009
Prostate cancer: to screen or not to screen?Urs E Studer, Laurence ColletteUrologic Oncology|November 11, 2010
What can be concluded from the ERSPC and PLCO trial data?Urs E Studer, Laurence CollettePageof 30